183 related articles for article (PubMed ID: 10788604)
1. Cytokine therapy for cancer.
Tagawa M
Curr Pharm Des; 2000 Apr; 6(6):681-99. PubMed ID: 10788604
[TBL] [Abstract][Full Text] [Related]
2. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
3. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins.
Xiang J
Hum Antibodies; 1999; 9(1):23-36. PubMed ID: 10331183
[TBL] [Abstract][Full Text] [Related]
4. Molecular immunological approaches to biotherapy of human cancers--a review, hypothesis and implications.
Becker Y
Anticancer Res; 2006; 26(2A):1113-34. PubMed ID: 16619514
[TBL] [Abstract][Full Text] [Related]
5. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
[TBL] [Abstract][Full Text] [Related]
6. Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy.
Hutmacher C; Neri D
Adv Drug Deliv Rev; 2019 Feb; 141():67-91. PubMed ID: 30201522
[TBL] [Abstract][Full Text] [Related]
7. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
8. Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen.
Tüting T; Gambotto A; Robbins PD; Storkus WJ; DeLeo AB
Gene Ther; 1999 Apr; 6(4):629-36. PubMed ID: 10476222
[TBL] [Abstract][Full Text] [Related]
9. Periodically Pulsed Immunotherapy in a Mathematical Model of Tumor, CD4
Wei HC; Yu JL; Hsu CY
Comput Math Methods Med; 2017; 2017():2906282. PubMed ID: 29250133
[TBL] [Abstract][Full Text] [Related]
10. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.
Liu M; Wang H; Liu L; Wang B; Sun G
J Transl Med; 2016 Jun; 14(1):155. PubMed ID: 27246873
[TBL] [Abstract][Full Text] [Related]
11. Fighting cancers from within: augmenting tumor immunity with cytokine therapy.
Pellegrini M; Mak TW; Ohashi PS
Trends Pharmacol Sci; 2010 Aug; 31(8):356-63. PubMed ID: 20561689
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic manipulation of the immune system: enhancement of innate and adaptive mucosal immunity.
Boyaka PN; Tafaro A; Fischer R; Fujihashi K; Jirillo E; McGhee JR
Curr Pharm Des; 2003; 9(24):1965-72. PubMed ID: 12871182
[TBL] [Abstract][Full Text] [Related]
13. T helper type 1/T helper type 2 cytokines and T cell death: preventive effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1)-mediated apoptosis of CD4+ T cells from human immunodeficiency virus-infected persons.
Estaquier J; Idziorek T; Zou W; Emilie D; Farber CM; Bourez JM; Ameisen JC
J Exp Med; 1995 Dec; 182(6):1759-67. PubMed ID: 7500020
[TBL] [Abstract][Full Text] [Related]
14. The changes in the T helper 1 (Th1) and T helper 2 (Th2) cytokine balance during HIV-1 infection are indicative of an allergic response to viral proteins that may be reversed by Th2 cytokine inhibitors and immune response modifiers--a review and hypothesis.
Becker Y
Virus Genes; 2004 Jan; 28(1):5-18. PubMed ID: 14739648
[TBL] [Abstract][Full Text] [Related]
15. Paracrine cytokine adjuvants in cancer immunotherapy.
Pardoll DM
Annu Rev Immunol; 1995; 13():399-415. PubMed ID: 7612229
[TBL] [Abstract][Full Text] [Related]
16. Antibody-cytokine fusion proteins for improving efficacy and safety of cancer therapy.
Valedkarimi Z; Nasiri H; Aghebati-Maleki L; Majidi J
Biomed Pharmacother; 2017 Nov; 95():731-742. PubMed ID: 28888210
[TBL] [Abstract][Full Text] [Related]
17. Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.
Young PA; Morrison SL; Timmerman JM
Semin Oncol; 2014 Oct; 41(5):623-36. PubMed ID: 25440607
[TBL] [Abstract][Full Text] [Related]
18. Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer.
Song K; Chang Y; Prud'homme GJ
Gene Ther; 2000 Mar; 7(6):481-92. PubMed ID: 10757021
[TBL] [Abstract][Full Text] [Related]
19. Modulation of antitumor immune responses by hematopoietic cytokines.
Waller EK; Ernstoff MS
Cancer; 2003 Apr; 97(7):1797-809. PubMed ID: 12655538
[TBL] [Abstract][Full Text] [Related]
20. Th1 polarization and apoptosis-inducing activity of CD4+ T -cells in cytokine-induced killers might favor the antitumor cytotoxicity of cytokine-induced killers in vivo.
Yu J; Ren X; Cao S; Zhang W; Hao X
Cancer Biother Radiopharm; 2006 Jun; 21(3):276-84. PubMed ID: 16918305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
